2024
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial.
Grilo C, Ivezaj V, Tek C, Yurkow S, Wiedemann A, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal Of Psychiatry 2024 PMID: 39659158, DOI: 10.1176/appi.ajp.20230982.Peer-Reviewed Original ResearchCognitive-behavioral therapyBinge-eating disorderEffectiveness of cognitive-behavioral therapyBinge-eating remission ratesEating-disorder psychopathologyCognitive behavioral therapyEvidence-based treatmentsRemission ratePercent weight lossHigher remission ratesBinge-eating frequencyBehavioral therapyPosttreatment assessmentLisdexamfetamineRandomized controlled trialsHeightened ratesCostly public health problemIntention-to-treat ratesFunctional impairmentWeight lossControlled trialsDisordersPosttreatmentIndividualized treatmentMixed models
2023
Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial
Grilo C, Lydecker J, Gueorguieva R. Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial. International Journal Of Eating Disorders 2023, 56: 1544-1553. PMID: 37144325, PMCID: PMC10524840, DOI: 10.1002/eat.23975.Peer-Reviewed Original ResearchConceptsInitial acute treatmentBinge-eating disorderCognitive behavioral therapyAcute treatmentBinge-eating frequencyInitial interventionTherapist-led cognitive behavioural therapyInitial pharmacological treatmentTreat remission ratesEvidence-based treatmentsSingle-site trialAcute efficacyRemission rateAdult patientsInitial treatmentPharmacological treatmentPatientsPosttreatment assessmentBehavioral treatmentSufficient benefitTherapyDisordersInterventionTreatmentPharmacotherapy
2022
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. American Journal Of Psychiatry 2022, 179: 927-937. PMID: 36285406, PMCID: PMC9722598, DOI: 10.1176/appi.ajp.20220267.Peer-Reviewed Original ResearchConceptsBehavioral weight loss therapyBinge-eating disorderPlacebo groupBupropion groupWeight lossRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialLogistic regressionBinge-eating remissionPlacebo-controlled trialWeight loss therapyDouble-blind placeboSerious public health problemPublic health problemEvidence-based treatmentsRate of participantsBinge-eating frequencyBinge Eating DisorderMedical comorbiditiesRemission rateLoss therapyPercent weight lossMixed modelsFunctional impairmentSecondary measures
2020
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study
Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical Therapeutics 2020, 43: 112-122.e1. PMID: 33218742, PMCID: PMC7902424, DOI: 10.1016/j.clinthera.2020.10.010.Peer-Reviewed Original ResearchConceptsBinge-eating disorderEating-disorder psychopathologyPilot RCTTreatment of BEDOutcome time pointDouble-blind treatmentPercentage of patientsControlled Pilot StudyDiscontinuation of medicationTreatment of bingeEvidence-based treatmentsBinge-eating frequencyBupropion combinationAdult patientsAdverse eventsComorbid obesitySecondary outcomesPrimary outcomeAcute effectsFunctional impairmentPlaceboLong-term effectsPatientsMost outcomesObesity
2019
Examining Race as a Predictor and Moderator of Treatment Outcomes for Binge-Eating Disorder: Analysis of Aggregated Randomized Controlled Trials
Lydecker JA, Gueorguieva R, Masheb R, White MA, Grilo CM. Examining Race as a Predictor and Moderator of Treatment Outcomes for Binge-Eating Disorder: Analysis of Aggregated Randomized Controlled Trials. Journal Of Consulting And Clinical Psychology 2019, 87: 530-540. PMID: 31008634, PMCID: PMC6589831, DOI: 10.1037/ccp0000404.Peer-Reviewed Original ResearchConceptsBinge-eating disorderWhite participantsCognitive behavioral therapySelf-report measuresTreatment outcomesBinge-eating remissionModerate treatment outcomeBinge Eating DisorderBinge-eating episodesMain effectBlack participantsWeight lossBehavioral weight lossEvidence-based treatmentsLower depressionTreatment researchRandomized Controlled TrialsBetter treatment outcomesControl conditionParticipantsControlled TrialsMultimodal treatmentPercent weight lossPatient groupModerator
2018
Impact of E-cigarettes on Smoking and Related Outcomes in Veteran Smokers With Psychiatric Comorbidity
Valentine GW, Hefner K, Jatlow PI, Rosenheck RA, Gueorguieva R, Sofuoglu M. Impact of E-cigarettes on Smoking and Related Outcomes in Veteran Smokers With Psychiatric Comorbidity. Journal Of Dual Diagnosis 2018, 14: 2-13. PMID: 29083287, PMCID: PMC7131866, DOI: 10.1080/15504263.2017.1384877.Peer-Reviewed Original ResearchConceptsE-cigarette usePsychiatric comorbidityCombustible cigarette useE-cigarettesVeteran smokersQuit ratesNicotine dependenceCigarette useVeterans Affairs Health Care SystemAlveolar carbon monoxide levelsOpen-label studySerious adverse eventsSmoking-related deathsFrequent e-cigarette useMain outcome measuresNumber of cigarettesOne-month followEvidence-based treatmentsTobacco-related harmSubstance use disordersGeneral U.S. populationLower quit ratesNicotine delivery systemsCombustible tobacco useHealth care system